LIVIVO - Search results -

Search results

Result 1 - 10 of total 368

Search options

Article ; Online: Preclinical and clinical imaging techniques as pathophysiological biomarkers - A preface to the special issue "Brain Imaging".

Villemagne, Victor L / Li, Yulong

2022 Volume 164, Issue 3, Page(s) 266–269

Abstract: Molecular imaging techniques have become important tools to characterize and measure biological processes at the cellular and molecular levels. Nowadays, molecular imaging techniques are widely used in preclinical and clinical studies to assess the ... ...

Abstract	Molecular imaging techniques have become important tools to characterize and measure biological processes at the cellular and molecular levels. Nowadays, molecular imaging techniques are widely used in preclinical and clinical studies to assess the molecular dynamics under physiological conditions and during pathological processes. This special issue on Brain Imaging (https://onlinelibrary.wiley.com/doi/toc/10.1111/[ISSN]1471-4159.brain-imaging) will highlight some of the recent advances in developing new tools and applying molecular imaging techniques to understand biomarker dynamics in health and diseases.
MeSH term(s)	Positron-Emission Tomography/methods ; Brain ; Biomarkers ; Molecular Imaging/methods
Chemical Substances	Biomarkers
Language	English
Publishing date	2022-11-16
Publishing country	England
Document type	Editorial
ZDB-ID	80158-6
ISSN	1471-4159 ; 0022-3042 ; 1474-1644
ISSN (online)	1471-4159
ISSN	0022-3042 ; 1474-1644
DOI	10.1111/jnc.15705
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.170: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Molecular Imaging of Neurodegeneration: The Way to New Horizons.

Villemagne, Victor L / Barthel, Henryk

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

2022 Volume 63, Issue Suppl 1, Page(s) 1S

MeSH term(s)	Molecular Imaging ; Positron-Emission Tomography
Language	English
Publishing date	2022-06-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	80272-4
ISSN	1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
ISSN (online)	1535-5667
ISSN	0097-9058 ; 0161-5505 ; 0022-3123
DOI	10.2967/jnumed.121.264237
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 328: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: EDITOR SPOTLIGHT: Interview with Brain Imaging Special Issue guest editors Victor Villemagne and Yulong Li.

Kwan, Kim H / Villemagne, Victor L / Li, Yulong

Journal of neurochemistry

2023 Volume 164, Issue 3, Page(s) 262–265

MeSH term(s)	Brain ; Head ; Neuroimaging
Language	English
Publishing date	2023-01-30
Publishing country	England
Document type	Editorial
ZDB-ID	80158-6
ISSN	1471-4159 ; 0022-3042 ; 1474-1644
ISSN (online)	1471-4159
ISSN	0022-3042 ; 1474-1644
DOI	10.1111/jnc.15758
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.170: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Selective Tau Imaging:

Villemagne, Victor L

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

2017 Volume 59, Issue 2, Page(s) 175–176

MeSH term(s)	Humans ; Molecular Imaging/methods ; Positron-Emission Tomography ; Radiopharmaceuticals ; tau Proteins/metabolism
Chemical Substances	Radiopharmaceuticals ; tau Proteins
Language	English
Publishing date	2017-09-21
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	80272-4
ISSN	1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
ISSN (online)	1535-5667
ISSN	0097-9058 ; 0161-5505 ; 0022-3123
DOI	10.2967/jnumed.117.198325
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 328: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Future Directions in Molecular Imaging of Neurodegenerative Disorders.

Barthel, Henryk / Villemagne, Victor L / Drzezga, Alexander

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

2022 Volume 63, Issue Suppl 1, Page(s) 68S–74S

Abstract: The improvement of existing techniques and the development of new molecular imaging methods are an exciting and rapidly developing field in clinical care and research of neurodegenerative disorders. In the clinic, molecular imaging has the potential to ... ...

Abstract	The improvement of existing techniques and the development of new molecular imaging methods are an exciting and rapidly developing field in clinical care and research of neurodegenerative disorders. In the clinic, molecular imaging has the potential to improve early and differential diagnosis and to stratify and monitor therapy in these disorders. Meanwhile, in research, these techniques improve our understanding of the underlying pathophysiology and pathobiochemistry of these disorders and allow for drug testing. This article is an overview on our perspective on future developments in neurodegeneration tracers and the associated imaging technologies. For example, we predict that the current portfolio of β-amyloid and tau aggregate tracers will be improved and supplemented by tracers allowing imaging of other protein aggregation pathologies, such as α-synuclein and transactive response DNA binding protein 43 kDa. Future developments will likely also be observed in imaging neurotransmitter systems. This refers to both offering imaging to a broader population in cases involving the dopaminergic, cholinergic, and serotonergic systems and making possible the imaging of systems not yet explored, such as the glutamate and opioid systems. Tracers will be complemented by improved tracers of neuroinflammation and synaptic density. Technologywise, the use of hybrid PET/MRI, dedicated brain PET, and total-body PET scanners, as well as advanced image acquisition and processing protocols, will open doors toward broader and more efficient clinical use and novel research applications. Molecular imaging has the potential of becoming a standard and essential clinical and research tool to diagnose and study neurodegenerative disorders and to guide treatments. On that road, we will need to redefine the role of molecular imaging in relation to that of emerging blood-based biomarkers. Taken together, the unique features of molecular imaging-that is, the potential to provide direct noninvasive information on the presence, extent, localization, and quantity of molecular pathologic processes in the living body-together with the predicted novel tracer and imaging technology developments, provide optimism about a bright future for this approach to improved care and research on neurodegenerative disorders.
MeSH term(s)	Brain/metabolism ; Humans ; Molecular Imaging ; Neurodegenerative Diseases/diagnostic imaging ; Neurodegenerative Diseases/metabolism ; Positron-Emission Tomography/methods ; Tomography, X-Ray Computed
Language	English
Publishing date	2022-06-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	80272-4
ISSN	1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
ISSN (online)	1535-5667
ISSN	0097-9058 ; 0161-5505 ; 0022-3123
DOI	10.2967/jnumed.121.263202
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 328: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Amyloid imaging: Past, present and future perspectives.

Villemagne, Victor L

Ageing research reviews

2016 Volume 30, Page(s) 95–106

Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the gradual onset of dementia. The pathological hallmarks of the disease are Aβ amyloid plaques, and tau neurofibrillary tangles, along dendritic and synaptic loss and ... ...

Abstract	Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the gradual onset of dementia. The pathological hallmarks of the disease are Aβ amyloid plaques, and tau neurofibrillary tangles, along dendritic and synaptic loss and reactive gliosis. Functional and molecular neuroimaging techniques such as positron emission tomography (PET) using functional and molecular tracers, in conjuction with other Aβ and tau biomarkers in CSF, are proving valuable in the differential diagnosis of AD, as well as in establishing disease prognosis. With the advent of new therapeutic strategies, there has been an increasing application of these techniques for the determination of Aβ burden in vivo in the patient selection, evaluation of target engagement and assessment of the efficacy of therapeutic approaches aimed at reducing Aβ in the brain.
MeSH term(s)	Alzheimer Disease/diagnostic imaging ; Amyloid beta-Peptides/analysis ; Amyloid beta-Peptides/cerebrospinal fluid ; Amyloidosis/diagnostic imaging ; Animals ; Biomarkers ; Humans ; Magnetic Resonance Imaging ; Neuroimaging ; Positron-Emission Tomography ; tau Proteins/analysis ; tau Proteins/cerebrospinal fluid
Chemical Substances	Amyloid beta-Peptides ; Biomarkers ; tau Proteins
Language	English
Publishing date	2016-01-28
Publishing country	England
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2075672-0
ISSN	1872-9649 ; 1568-1637
ISSN (online)	1872-9649
ISSN	1568-1637
DOI	10.1016/j.arr.2016.01.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5579: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Can amyloid PET differentiate "pure" LBD from AD with or without LBD copathology?

Landau, Susan M / Villemagne, Victor L

Neurology

2019 Volume 94, Issue 3, Page(s) 103–104

MeSH term(s)	Dementia ; Humans ; Lewy Bodies ; Lewy Body Disease ; Neuropathology ; Positron-Emission Tomography
Language	English
Publishing date	2019-12-20
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	207147-2
ISSN	1526-632X ; 0028-3878
ISSN (online)	1526-632X
ISSN	0028-3878
DOI	10.1212/WNL.0000000000008812
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.153: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 18: Show issues
Zs.MO 374: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Advances in Brain Amyloid Imaging.

Krishnadas, Natasha / Villemagne, Victor L / Doré, Vincent / Rowe, Christopher C

Seminars in nuclear medicine

2021 Volume 51, Issue 3, Page(s) 241–252

Abstract: Amyloid-β (Aβ) PET imaging has now been available for over 15 years. The ability to detect Aβ in vivo has greatly improved the clinical and research landscape of Alzheimer's disease (AD) and other neurodegenerative conditions. Aβ imaging provides very ... ...

Abstract	Amyloid-β (Aβ) PET imaging has now been available for over 15 years. The ability to detect Aβ in vivo has greatly improved the clinical and research landscape of Alzheimer's disease (AD) and other neurodegenerative conditions. Aβ imaging provides very reliable, accurate, and reproducible measurements of regional and global Aβ burden in the brain. It has proved invaluable in anti-Aβ therapy trials, and is now recognized as a powerful diagnostic tool. The appropriate use of Aβ PET, when combined with comprehensive clinical evaluation by a dementia-trained specialist, can improve the accuracy of a clinical diagnosis of AD and substantially alter management. It can assist in differentiating AD from other neurodegenerative conditions, often by its ability to rule out the presence of Aβ. When combined with tau imaging, further increase in specificity for the diagnosis of AD can be achieved. The integration of Aβ PET, in conjunction with biomarkers of tau, neurodegeneration and neuroinflammation, into large, longitudinal, observational cohort studies continues to increase our understanding of the development of AD. Its incorporation into clinical trials has been pivotal in defining the most effective anti-Aβ biological therapies and optimal dosing so that effective disease modifying therapy now appears imminent. Aβ deposition is a gradual and protracted process, permitting a wide treatment window for anti-Aβ therapies and Aβ PET has made trials in this preclinical AD period feasible. Continuing improvement in Aβ tracer target to background ratio is allowing trials in earlier AD that tailor drug dosage to Aβ level. The quest to standardize quantification and define universally applicable thresholds for all Aβ tracers has produced the Centiloid method. Centiloid values that correlate well with neuropathologic findings and prognosis have been identified. Rapid cloud-based automated individual scan analysis is now possible and does not require MRI. Challenges remain, particularly around cross camera standardized uptake value ratio variation that need to be addressed. This review will compare available Aβ radiotracers, discuss approaches to quantification, as well as the clinical and research applications of Aβ PET.
MeSH term(s)	Alzheimer Disease/diagnostic imaging ; Amyloid beta-Peptides/metabolism ; Biomarkers ; Brain/diagnostic imaging ; Brain/metabolism ; Humans ; Positron-Emission Tomography ; tau Proteins/metabolism
Chemical Substances	Amyloid beta-Peptides ; Biomarkers ; tau Proteins
Language	English
Publishing date	2021-01-19
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	120248-0
ISSN	1558-4623 ; 0001-2998
ISSN (online)	1558-4623
ISSN	0001-2998
DOI	10.1053/j.semnuclmed.2020.12.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 763: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Imaging of Reactive Astrogliosis by Positron Emission Tomography.

Harada, Ryuichi / Furumoto, Shozo / Kudo, Yukitsuka / Yanai, Kazuhiko / Villemagne, Victor L / Okamura, Nobuyuki

Frontiers in neuroscience

2022 Volume 16, Page(s) 807435

Abstract: Many neurodegenerative diseases are neuropathologically characterized by neuronal loss, gliosis, and the deposition of misfolded proteins such as β-amyloid (Aβ) plaques and tau tangles in Alzheimer's disease (AD). In postmortem AD brains, reactive ... ...

Abstract	Many neurodegenerative diseases are neuropathologically characterized by neuronal loss, gliosis, and the deposition of misfolded proteins such as β-amyloid (Aβ) plaques and tau tangles in Alzheimer's disease (AD). In postmortem AD brains, reactive astrocytes and activated microglia are observed surrounding Aβ plaques and tau tangles. These activated glial cells secrete pro-inflammatory cytokines and reactive oxygen species, which may contribute to neurodegeneration. Therefore,
Language	English
Publishing date	2022-02-08
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2411902-7
ISSN	1662-453X ; 1662-4548
ISSN (online)	1662-453X
ISSN	1662-4548
DOI	10.3389/fnins.2022.807435
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Tau in dementia with Lewy bodies.

Chin, Kai Sin / Churilov, Leonid / Doré, Vincent / Villemagne, Victor L / Rowe, Christopher C / Yassi, Nawaf / Watson, Rosie

The Australian and New Zealand journal of psychiatry

2023 Volume 58, Issue 2, Page(s) 175–182

Abstract: Objective: Neurofibrillary tangles are present in a proportion of people with dementia with Lewy bodies and may be associated with worse cognition. Recent advances in biomarkers for Alzheimer's disease include second-generation tau positron emission ... ...

Abstract	Objective: Neurofibrillary tangles are present in a proportion of people with dementia with Lewy bodies and may be associated with worse cognition. Recent advances in biomarkers for Alzheimer's disease include second-generation tau positron emission tomography as well as the detection of phosphorylated tau at threonine 181 (p-tau181) in plasma. This study aimed to investigate tau in people with dementia with Lewy bodies using a second-generation tau positron emission tomography tracer as well as plasma p-tau181. Methods: Twenty-seven participants (mean age 74.7 ± 5.5) with clinically diagnosed probable dementia with Lewy bodies underwent comprehensive clinical assessment and positron emission tomography imaging ( Results: Five dementia with Lewy bodies participants (18.5%) had an abnormal tau positron emission tomography (increased tau uptake in the temporal meta-region-of-interest). Higher plasma p-tau181 concentrations correlated with higher tau deposition in the temporal region (ρ = 0.46, 95% confidence interval = [0.10, 0.72]) and classified abnormal tau positron emission tomography in dementia with Lewy bodies with an area under the curve of 0.95 (95% confidence interval = [0.86, 0.99]). Plasma p-tau181 also correlated positively with cortical amyloid-beta binding (ρ = 0.68, 95% confidence interval = [0.40, 0.84]) and classified abnormal amyloid-beta positron emission tomography in dementia with Lewy bodies with an area under the curve of 0.91 (95% confidence interval = [0.79, 0.99]). There was no association found between tau deposition and any of the clinical variables. Conclusions: Tau is a common co-pathology in dementia with Lewy bodies. Plasma p-tau181 correlated with abnormal tau and amyloid-beta positron emission tomography and may potentially be used as a marker to identify co-morbid Alzheimer's disease-related pathology in dementia with Lewy bodies. The clinical implications of tau in dementia with Lewy bodies need to be further evaluated in larger longitudinal studies.
MeSH term(s)	Aged ; Aged, 80 and over ; Humans ; Alzheimer Disease/diagnostic imaging ; Amyloid beta-Peptides/metabolism ; Biomarkers ; Lewy Body Disease/diagnostic imaging ; Positron-Emission Tomography/methods ; tau Proteins/metabolism
Chemical Substances	Amyloid beta-Peptides ; Biomarkers ; tau Proteins ; MAPT protein, human
Language	English
Publishing date	2023-06-01
Publishing country	England
Document type	Journal Article
ZDB-ID	221140-3
ISSN	1440-1614 ; 0004-8674
ISSN (online)	1440-1614
ISSN	0004-8674
DOI	10.1177/00048674231177219
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 856: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito